INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 64 filers reported holding INFINITY PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $426,000 | +161.3% | 157,247 | +84.1% | 0.02% | +150.0% |
| Q2 2018 | $163,000 | +3975.0% | 85,412 | +3458.8% | 0.01% | – |
| Q2 2017 | $4,000 | -97.7% | 2,400 | -95.5% | 0.00% | -100.0% |
| Q1 2017 | $173,000 | +133.8% | 53,700 | -1.5% | 0.02% | +88.9% |
| Q4 2016 | $74,000 | +252.4% | 54,500 | +300.7% | 0.01% | +350.0% |
| Q3 2016 | $21,000 | -12.5% | 13,600 | -25.7% | 0.00% | -33.3% |
| Q2 2016 | $24,000 | +100.0% | 18,300 | +698.1% | 0.00% | +50.0% |
| Q1 2016 | $12,000 | -70.0% | 2,293 | -55.2% | 0.00% | -66.7% |
| Q4 2015 | $40,000 | -46.7% | 5,123 | -25.8% | 0.01% | -40.0% |
| Q2 2015 | $75,000 | +66.7% | 6,900 | +115.6% | 0.01% | +66.7% |
| Q1 2015 | $45,000 | -75.8% | 3,200 | -70.9% | 0.01% | -77.8% |
| Q4 2014 | $186,000 | +675.0% | 11,000 | +450.0% | 0.03% | +800.0% |
| Q1 2014 | $24,000 | +242.9% | 2,000 | +300.0% | 0.00% | +200.0% |
| Q4 2013 | $7,000 | -58.8% | 500 | -50.0% | 0.00% | -66.7% |
| Q3 2013 | $17,000 | -89.6% | 1,000 | -90.0% | 0.00% | -91.4% |
| Q2 2013 | $163,000 | -95.2% | 10,048 | -85.8% | 0.04% | -94.5% |
| Q1 2013 | $3,419,000 | – | 70,548 | – | 0.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |